DOCSLIB.ORG

Adrenal & Thyroid Pharmacotherapy Thyroid Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adrenal & Thyroid Pharmacotherapy Thyroid Disorders 2/28/17 Overview of Topics • Thyroid Disorders • Hypothyroidism • Myxedema Coma/Stupor • Hyperthyroidism Adrenal & Thyroid • Thyroid Storm • Euthyroid Sick Syndrome Pharmacotherapy • Adrenocor/cal Insufficiency Sarah A. Myers, PharmD Candidate • ACute & ChroniC management January 18, 2017 • Glucocorcoids Objectives • Understand the physiology of the thyroid gland, hypothalamiC-pituitary-adrenal axis, and hormones • IdenIfy the signs and symptoms of various thyroid disorders Thyroid Disorders & • DisCuss appropriate uses of mediCaons in the treatment of various thyroid disorders and adrenal insuffiCienCy Pharmacotherapy The Thyroid Thyroid Hormones • BuQerfly-shaped organ responsible for synthesizing and Thyroid folliCular Cells produCe two primary hormones: releasing thyroid hormones • Tetraiodothyronine (thyroxin, T4) • Minimal hormonal acIvity (prohormone) • Serves as a reservoir for Conversion to T3 • Thyroid hormones have an effeCt on virtually every organ system in the body • Triiodothyronine (T3) • Most potent in binding nuClear reCeptors • Children: CriICal for groWth and development • Less than 20% of T3 is produCed in the thyroid gland • Adults: metaboliC stability • Primarily formed by breakdoWn of T4 in the peripheral Issues InacIve produCt of T4 deiodinaon: • Thyroid folliCles: struCtural & funCIonal units • Reverse Triiodothyronine (rT3) • No metaboliC/physiologiC funCIon • Only organ Capable of absorbing iodine • Thyroid hormones Composed of: Iodine and tyrosine Pappa, 2011; Umpierrez, 2002 1 2/28/17 Thyroid Hormones Hormone Synthesis Thyroid peroxidase Dipiro, 2010 Häggström, 2014 Thyroid Hormone Regulation Peripheral Thyroid Function Nega/ve FeedBack InhiBi/on TRH: Thyrotropin- • T4 and T3 are 99% protein bound releasing hormone • T3 is the reCeptor-acIve thyroid hormone • T4 ! T3 in peripheral Issues by iodothyronine deiodinase • Pharmacologic target in hyperthyroidism TSH: Thyroid- sImulang hormone • T3 binds to two speCifiC nuClear reCeptors • Thyroid hormone reCeptor alpha and beta • Regulates expression of many genes involved in numerous physiologic funcons • InCreases Issue thermogenesis and basal metaboliC rate emediCine.medsCape.Com/arICle/122393-overvieW Drug-Induced Thyroid Hormone Changes Effect on thyroid hormone Select medicaons Decreased TSH Dopamine agonists, gluCoCorICoids Increased TSH MetoClopramide, domperidone Decreased T3/T4 secreon Lithium, Iodide, amiodarone Increased T3/T4 secre/on Iodide, amiodarone Increased TBG binding Estrogens (pregnanCy), tamoxifen, methadone/ heroin/methadone, fluouracil, mitotane Decreased TBG binding Androgens/anaboliC steroids, gluCoCorICoids, heparin, saliCylates, furosemide (high-doses) Increased Thyroid Phenobarbital, phenytoin, rifampin, MetaBolism Carbamazepine Decreased T4 ! T3 PTU, B-blockers, amiodarone, glucocorcoids conversion HYPOTHYROIDISM Garber J, Cobin R, Woeber K, et al 2 2/28/17 Hypothyroidism Hypothyroidism Hypothyroidism Hyperthyroidism • Primary Hypothyroidism—insuffiCient funCIon of the thyroid Symptoms Weight gain Weight loss (inCreased appeIte) • Elevated TSH and loW free T4 ConsIpaon Nervousness • Overt Weakness Anxiety • Elevated TSH and normal free T4 Lethargy Palpitaons Depression EmoIonal lability • SubCliniCal Dry skin Menstrual disturbanCes MusCle Cramps, myalgia Heat intoleranCe • Secondary Hypothyroidism—insuffiCient sImulaon of the Menorrhagia thyroid Cold intoleranCe • Central hypothyroidism—HypothalamiC or pituitary Signs Weakness (proximal Warm, moist skin muscles) Exophthalmos (Grave’s) • LoW free T4 Without elevated TSH SloW DRTs PreIbial myxedema (Grave’s) Coarse hair/skin Fine hair Cold dry skin TachyCardia Periorbital puffiness Fine tremor BradyCardia HyperacIve DTRs SloW, hoarse speeCh Thyromegaly Garber J, Cobin R, Woeber K, et al , 2012. Medication-Induced Hypothyroidism Hypothyroidism • Common eologies of Primary Hypothyroidism • Iodine defiCienCy Medica/ons causing Hypothyroidism • most Common Cause worldwide InhibiIon of thyroid hormone synthesis/ Lithium release Aminoglutethimide Iodine-Containing drugs • ChroniC autoimmune thyroidiIs (Hashimoto’s thyroidiIs) (Amiodarone, guaifenesin) • Most Common Cause in areas of iodine suffiCienCy (U.S.) TSH suppression Dopamine • Autoimmune thyroid disease 5-10 Imes more Common in DestruCIve thyroidiIs Suninib females InCreased type-3 deiodinaon Sorafenib InCreased T4 ClearanCe and suppression of Bexarotene • Thyroid CarCinoma TSH • RadioacIve iodine or surgiCal treatment for hyperthyroid • MediCaon-induCed Garber J, Cobin R, Woeber K, et al , 2012. Garber J, Cobin R, Woeber K, et al , 2012. Hypothyroidism: Screening Treatment: Hypothyroidism • AmeriCan Thyroid AssoCiaon: Goals of Treatment: • Women and men >35 years of age—sCreen every 5 years • Restore euthyroid state • Resolve signs/symptoms of hypothyroidism • AmeriCan AssoCiaon of CliniCal EndoCrinologists • Avoid thyrotoxiCosis • Older paents (espeCially Women), no speCifiC age reCommendaon Thyroid Replacement Products • Levothyroxine (T4) • AmeriCan ACademy of Family PhysiCians • • Paents 60 years of age and older (no frequenCy) Liothyronine (T3) • Levothyroxine/liothyronine (T3/T4) • DesiCCated thyroid (T3/T4) 3 2/28/17 Levothyroxine, T4 Levothyroxine Dosing Synthroid, Tirosint, Tirosint-Sol, Levoxyl, Unithroid Narrow therapeuc range: Careful dose Itraon to avoid under- or over- treatment • Dosing based on age, Weight, CardiovasCular status Treatment of choice for hypothyroidism (ATA/AACE) • Thyroid replacement dose (overt): 1.6 mcg/kg/day • Healthy adults age <50 years can be iniBated on full replacement MOA: T4 Converted to acIve metabolite T3, WhiCh binds to dose thyroid reCeptor proteins in the nuCleus to exert metaboliC • Adults <50 years With Cardiac disease: iniIate at 25-50 mCg/day, effeCts through Control of DNA transCripIon and protein Itrate by 12.5 to 25 mCg every 6 to 8 Weeks synthesis • Adults >50 years Without Cardiac disease: iniIate at 25-50 mCg/day, Itrate by 12.5 to 25 mCg every 6 to 8 Weeks • Adults >50 years With Cardiac disease: iniIate 12.5-25 mCg/day, IndiCaons: Hypothyroidism, pituitary TSH suppression, Myxedema Coma Itrate by 12.5 to 25 mCg every 6 to 8 Weeks • Thyroid replacement (suBclinical, if treated): 1 mcg/kg/day Available dosage forms: tablets, Capsules, IV soluIon, oral soluIon* Garber J, Cobin R, Woeber K, et al , 2012.; AbbVie, 2010. Garber J, Cobin R, Woeber K, et al , 2012.; AbbVie, 2010. Levothyroxine Dosing Levothyroxine, T4 Monitoring (TSH and free T4) • TSH every 4-8 weeks aer dose Changes/iniIaon unIl euthyroid • TSH 6 months aer euthyroid on stable dose • TSH every 12 months thereaer Contraindicaons: • ACute MI, unCorreCted adrenal insuffiCienCy, thyrotoxiCosis • Adrenal insuffiCienCy: glucocorBcoid treatment should precede levothyroxine Garber J, Cobin R, Woeber K, et al , 2012.; AbbVie, 2010. Garber J, Cobin R, Woeber K, et al , 2012.; AbbVie, 2010. Levothyroxine: Interactions Treatment: Hypothyroidism Drugs decreasing aBsorpon of levothyroxine: Not recommended by AACE for replacement therapy • Antacids (aluminum, magnesium), Bile acid sequestrants • Desiccated thyroid (Armour Thyroid) (Cholestyramine, colespol), CalCium Carbonate, Caon • Natural, porCine-derived thyroid (T3-T4 Combinaon, 1:4 rao) exChange resins (Kayexalate), ferrous sulfate, Orlistat, • Dosed in grains simethiCone, suCralfate • Preparaons may Contain less prediCtable potenCy • Liothyronine, T3 (Cytomel, Triostat IV) Drugs increasing metaBolism: • Liothyronine- levothyroxine, T3/T4 (Thyrolar) • Rifampin, Carbamazepine, phenobarbital, phenytoin Thyroid replacement produCt Conversions: Drugs reducing protein binding of levothyroxine: 100 mcg levothyroxine = 60-65 mg (1 grain) desiccated thyroid • Heparin, SaliCylates (>2 g/day), phenytoin, mefenamiC acid, = 25 mcg liothyronine (T3) = 12.5 mcg T3/ 50 mcg T4 (Liotrix) furosemide (>80mg IV) Garber J, Cobin R, Woeber K, et al , 2012. Garber J, Cobin R, Woeber K, et al , 2012. 4 2/28/17 Myxedema Coma Myxedema Coma Extreme manifestaon of hypothyroidism With mulIple organ abnormaliIes and mental deterioraon • OCCurs When Compensatory responses are overWhelmed by a preCipitang factor (infeCIon, trauma) Presentaon: • DeCreased mental status • Hypothermia (<35.5 C) • Hypotension • HypovenIlaon MatheW V, Ahmadmisgar R, Chowdhury S, et al., 2011 Myxedema Coma Prompt treatment should inClude: • Thyroid hormone replacement Monotherapy dose Combinaon therapy dose levothyroxine 300-500 mCg IVP, then 200-400 mCg IVP, then 50-100 mCg 50-100 mCg daily daily triiodothyronine 25-50 mCg IVP, then 5-20 mCg IVP, then 2.5-10 mCg Q8H Q4-12H • ICU treatment • Intubaon • CorreCt hypotension and eleCtrolytes • Treatment of preCipitang factors • Stress steroids • HydroCorIsone 50-100mg IV Q6H HYPERTHYROIDISM MacKerroW S, Osborn L, Levy H et al., 2009; MatheW V, Ahmadmisgar R, Chowdhury S, et al., 2011; Ross D, 2015. Hyperthyroidism Hyperthyroidism Overacve thyroid or thyrotoxicosis • Endogenous hyperthyroidism most Commonly due to Graves • Inappropriately high produCIon and seCreIon of thyroid Disease hormone • Autoimmune disorder in WhiCh thyrotropin reCeptor anIbodies (TRAb) sImulate TSH reCeptor, inCreasing thyroid hormone produCIon and release Overt hyperthyroidism • LoW/undeteCtable serum TSH With elevated free T4 or T3 • Thyroid CarCinoma, ovarian tumors, pituitary tumors Subclinical hyperthyroidism • MediCaon-induCed hyperthyroidism • LoW/undeteCtable serum TSH With relavely normal serum T4 and T3 • Iodine • Amiodarone (up to 12% treated pts, Contains up to 37% iodine) • Levothyroxine Ross D,
Load more

Recommended publications
  • Thyroid Disease Update
    10/11/2017 Thyroid Disease Update • Donald Eagerton M.D. Disclosures I have served as a clinical investigator and/or speakers bureau member for the following: Abbott, Astra Zenica, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi Aventis Thyroid Disease Update • Hypothyroidism • Hyperthyroidism • Thyroid Nodules • Thyroid Cancer 1 10/11/2017 2 10/11/2017 Case 1 • 50 year old white female is seen for follow up. Notices cold intolerance, dry skin, and some fatigue. Cholesterol is higher than prior visits. • Family history; Mother had history of hypothyroidism. Sister has hypothyroidism. • TSH = 14 (0.30- 3.3) Free T4 = 1.0 (0.95- 1.45) • Weight 70 kg Case 1 • Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound Case 1 Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound 3 10/11/2017 Hypothyroidism • Incidence 0.1- 2.0 % of the population • Subclinical hypothyroidism in 4-10% of the adult population • 5-8 times higher in women An FT4 test can confirm hypothyroidism 13 • In the presence of high TSH and FT4 levels in relation to the thyroid function TSH, low FT4 (free thyroxine) usually signalsTSH primary hypothyroidism12 Overt Mild Mild Overt Euthyroidism FT4 Hypothyroidism Thyrotoxicosis* Thyrotoxicosis vs. hyperthyroidism¹ While these terms are often used interchangeably, thyrotoxicosis (toxic thyroid), describes presence of too much thyroid hormone, whether caused by thyroid overproduction (hyperthyroidism); by leakage of thyroid hormone into the bloodstream (thyroiditis); or by taking too much thyroid hormone medication.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • Common Thyroid Disorders
    9/7/17 Common Louie Riesch MSN, MPH, RN, ACNS-BC, CDE Thyroid Texas Diabetes and Endocrinology Disorders Anatomy of the Thyroid Gland Hypothalamic-Pituitary-Thyroid Axis Physiology Hypothalamus TRH • TSH reflects tissue thyroid – hormone actions • TSH as an index of Pituitary therapeutic success and – potential toxicity TSH T4 Target Tissues T3 Heart Thyroid Gland Liver T4 T3 TR Bone T4 è T3 Liver CNS 1 9/7/17 Production of T4 and T3 Ê T4 is the primary secretory product of the thyroid gland, which is the only source of T4 Ê The thyroid secretes approximately 100 nmol of T4 per day Ê T3 is derived from 2 processes Ê The total daily production rate of T3 is about 15-30 µg Ê About 80% of circulating T3 comes from deiodination of T4 in peripheral tissues Ê Largely liver and kidneys Ê About 20% comes from direct thyroid secretion Free Hormone Concept Ê Only unbound (free) hormone has metabolic activity and physiologic effects Ê Total hormone concentration Ê Normally is kept proportional to the concentration of carrier proteins Ê Is kept appropriate to maintain a constant free hormone level 2 9/7/17 Drugs and Conditions That Increase Serum T4 and T3 Levels by Increasing TBG Drugs that increase TBG Conditions that increase TBG Ê Oral contraceptives and other Ê Pregnancy sources of estrogen Ê Infectious/chronic active Ê Methadone hepatitis Ê Clofibrate Ê HIV infection Ê 5-Fluorouracil Ê Biliary cirrhosis Ê Heroin Ê Acute intermittent porphyria Ê Tamoxifen Ê Genetic factors Evaluate for thyroid disease Ê All >35 years of age, every 5 years Ê
    [Show full text]
  • Metabolism of Reverse Triiodothyronine by Isolated Rat Hepatocytes
    Metabolism of reverse triiodothyronine by isolated rat hepatocytes. S J Rooda, … , M A van Loon, T J Visser J Clin Invest. 1987;79(6):1740-1748. https://doi.org/10.1172/JCI113014. Research Article Reverse triiodothyronine (rT3) is metabolized predominantly by outer ring deiodination to 3,3'-diiodothyronine (3,3'-T2) in the liver. Metabolism of rT3 and 3,3'-T2 by isolated rat hepatocytes was analyzed by Sephadex LH-20 chromatography, high performance liquid chromatography, and radioimmunoassay, with closely agreeing results. Deiodinase activity was inhibited with propylthiouracil (PTU) and sulfotransferase activity by sulfate depletion or addition of salicylamide or dichloronitrophenol. Normally, little 3,3'-T2 production from rT3 was observed, and 125I- was the main product of both 3, [3'-125I]T2 and [3',5'-125I]rT3. PTU inhibited rT3 metabolism but did not affect 3,3'-T2 clearance as explained by accumulation of 3,3'-T2 sulfate. Inhibition of sulfation did not affect rT3 clearance but 3,3'-T2 metabolism was greatly diminished. The decrease in I- formation from rT3 was compensated by an increased recovery of 3,3'-T2 up to 70% of rT3 metabolized. In conclusion, significant production of 3,3'-T2 from rT3 by rat hepatocytes is only observed if further sulfation is inhibited. Find the latest version: https://jci.me/113014/pdf Metabolism of Reverse Triiodothyronine by Isolated Rat Hepatocytes Sebo Jan Eelkman Rooda, Maria A. C. van Loon, and Thoo J. Vissef Department ofInternal Medicine III and Clinical Endocrinology, Erasmus University Medical School, Rotterdam, The Netherlands Abstract It deiodinates only the outer ring of substrates such as T4 and rT3 (2-4).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • United States Patent (10) Patent N0.: US 7,288,257 B2 Powell (45) Date of Patent: Oct
    US007288257B2 (12) United States Patent (10) Patent N0.: US 7,288,257 B2 Powell (45) Date of Patent: Oct. 30, 2007 (54) DIAGNOSIS AND TREATMENT OF HUMAN 5,342,788 A 8/1994 Kunst et a1. .............. .. 436/500 DORMANCY SYNDROME 5,691,456 A 11/1997 AdamcZyk et al. ....... .. 530/405 6,087,090 A 7/2000 Mascarenhas ................ .. 435/4 (76) Inventor: Michael Powell, 150 Catherine Lance, 2003/0007941 A1 1/2003 Cornelius et a1, Suite 1, Grass Valley, CA (US) 95945 ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 199 days. _ Hannah V. Carey, The American Physiological Society, Physical _ Rev 83; Mammalian Hibernation: Cellular and Molecular (21) Appl' NO" 10/444’845 Responses to Depressed Metabolism and Low Temperature, 2003, (22) Filed: May 23, 2003 PP' 1153'1181' _ _ _ Primary ExamineriRuth A Davis (65) Pnor Pubhcatlon Data (74) Attorney, Agent, or F irmiBorson LaW Group, PC; D. US 2003/0228628 A1 Dec. 11, 2003 Benjamin Borson Related US. Application Data (57) ABSTRACT (60) Provisional application No. 60/382,913, ?led on May $112002’ provlslonal apphcanon NO‘ 60/383’271’ New methods for diagnosis of human dormancy syndrome e on May 24’ 2002' are provided. Human dormancy syndrome is characterized (51) Int C1 by elevated serum ratio of rT3/iT 3 compared to a population 1462K 3'9/00 (2006 01) of normal subjects from Which subjects suffering from A 61K 38/22 (200601) ?bromyalgia, chronic fatigue, obesity, dementias including A 61K 38/27 (200601) AlZheimer’s Disease and related dormancy conditions are C1 2 Q 1/00 (200601) excluded, and the presence of one or more ?ndings related ' A / A / A to reduced activity including torpor, chronic fatigue, insulin (52) US.
    [Show full text]
  • Comprehensive Thyroid Plus Adrenal Report
    Comprehensive Thyroid Plus Adrenal Report Jane Doe SAMPLEDate Collected: 2/13/2017 Comprehensive Thyroid Plus Adrenal Report Patient Name: Doe, Jane Batch Number: B0000 Patient DOB: 12/10/1960 Accession Number: Q00000 Gender: F Date Received: 2/14/2017 Physician Jon Doe, ND Report Date: 2/22/2017 Test Patient Results Reference Value DHEAS µg/dL 0 125 250 375 500 107 35 - 430 TSH µIU/mL 0.020 1.260 2.500 3.740 4.980+ 7.030 0.358 - 3.74 T4, Total µg/dL 0.5 4.4 8.3 12.1 16.0 7.2 4.5 - 12.5 T3, Free pg/mL 0.5 1.9 3.3 4.6 6.0 3.6 2.2 - 4.0 T4, Free ng/dL 0.10 0.83 1.55 2.28 3.00 0.87 0.76 - 1.46 Cortisol µg/dL 0.2 11.4 22.6 33.8 45.0 6.5 3.1 - 22.4 AntiTPO Ab IU/mL 10.0 20.0 30.0 40.0 50.0 + > 1000.0 0.0 - 35.0 AntiThyroglobulin Ab IU/mL 20 30 40 50 60 + 97 ND - 40 Thyroglobulin ng/mL 0 20 40 60 80 38 <= 55 Thyroxinebinding globulin, TBG µg/mL SAMPLE0 11 23 34 45 20 14 - 31 10401 Town Park Drive, Houston, Texas 77072 USA CLIA# 45D0710715 (800)227-LABS(5227) / (713)-621-3101 James W. Jacobson, Ph.D., Laboratory Director Comprehensive Thyroid Plus Adrenal Report Patient Name: Doe, Jane Batch Number: B0000 Patient DOB: 12/10/1960 Accession Number: Q00000 Gender: F Date Received: 2/14/2017 Physician Jon Doe, ND Report Date: 2/22/2017 Test Component Flag Result Reference Range DHEA-S µg/dL 107 35 - 430 TSH µIU/mL H 7.030 0.358 - 3.74 T4, Total µg/dL 7.2 4.5 - 12.5 T3, Free pg/mL 3.6 2.2 - 4.0 T4, Free ng/dL 0.87 0.76 - 1.46 Cortisol µg/dL 6.5 3.1 - 22.4 Anti-TPO Ab IU/mL H > 1000.0 0.0 - 35.0 Anti-Thyroglobulin Ab IU/mL H 97 ND - 40 Thyroglobulin ng/mL 38 <= 55 Thyroxine-binding globulin, TBGSAMPLE µg/mL 20 14 - 31 10401 Town Park Drive, Houston, Texas 77072 USA CLIA# 45D0710715 (800)227-LABS(5227) / (713)-621-3101 James W.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • Hypothyroidism: Mimicker of Common Complaints Matthew C
    Emerg Med Clin N Am 23 (2005) 649–667 Hypothyroidism: Mimicker of Common Complaints Matthew C. Tews, DOa, Sid M. Shah, MD, FACEPb,*, Ved V. Gossain, MD, FACP, FACEPc aCollege of Osteopathic Medicine, Emergency Medicine Residency Program, Michigan State University–Lansing, P.O. Box 30480, Lansing, MI 48909, USA bMichigan State University, Attending Physician Emergency Medicine, Ingham Regional Medical, Center 401 W. Greenlawn Avenue, Lansing, MI 48910, USA cDivision of Endocrinology, Department of Medicine, Michigan State University, Lansing, MI 48909, USA Patients with hypothyroidism may present with vague symptoms such as fatigue, arthralgias, myalgias, muscle cramps, headaches, and ‘‘not feeling well.’’ These are also among the more common complaints encountered by the emergency physicians. The disease spectrum of hypothyroidism ranges from an asymptomatic, subclinical condition to the rare, life-threatening myxedema coma, and thus can be a challenging diagnosis to make. A progressive and chronic disease, hypothyroidism results from diminished thyroid hormone production. It slows metabolic functions in every organ system in the body. Commonly, clinical presentation of hypothyroidism can be confused with effects of aging in the elderly, musculoskeletal or a psychiatric illness such as depression in the younger patients. Spontaneously occurring hypothyroidism is relatively common, with prevalence between 1% to 2%, and is 10 times more common in women than in men [1]. The probability of developing spontaneous hypothyroidism increases with age, with women having a mean age at diagnosis of around 60 years [2]. A recent survey showed that 9.5% out of nearly 26,000 visitors to a statewide health fair in Colorado had elevated circulating thyroid stimulating hormone (TSH) levels, indicating underlying hypothyroidism [3].
    [Show full text]
  • Chang Et Al Thyroid
    Available online at www.sciencedirect.com Toxicology 243 (2008) 330–339 Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS)ଝ Shu-Ching Chang a, Julie R. Thibodeaux b,1, Mary L. Eastvold c, David J. Ehresman a, James A. Bjork d, John W. Froehlich e,2, Christopher Lau b, Ravinder J. Singh c, Kendall B. Wallace d, John L. Butenhoff a,∗ a Medical Department, 3M Company, St. Paul, MN 55144, United States b United States Environmental Protection Agency, ORD, NHEERL, Reproductive Toxicology Division, Research Triangle Park, NC 27711, United States c Mayo Clinic and Foundation, Department of Laboratory Medicine and Pathology, Rochester, MN 55095, United States d University of Minnesota, Medical School, Department of Biochemistry and Molecular Biology, Duluth, MN 55812, United States e Pace Analytical Services, Inc., Minneapolis, MN 55414, United States Received 29 August 2007; received in revised form 18 October 2007; accepted 20 October 2007 Available online 26 October 2007 Abstract Introduction: Perfluorooctanesulfonate (PFOS) is widely distributed and persistent in humans and wildlife. Prior toxicological studies have reported decreased total and free thyroid hormones in serum without a major compensatory rise in thyrotropin (TSH) or altered thyroid gland histology. Although these animals (rats, mice and monkeys) might have maintained an euthyroid state, the basis for hypothyroxinemia remained unclear. We undertook this study to investigate the causes for the PFOS-induced reduction of serum total thyroxine (TT4) in rats. Hypotheses: We hypothesized that exposure to PFOS may increase free thyroxine (FT4) in the rat serum due to the ability of PFOS to compete with thyroxine for binding proteins.
    [Show full text]
  • Ontogenesis of Iodothyronine-5'-Deiodinase
    Ontogenesis of iodothyronine-5'-deiodinase. Induction of 5'- deiodinating activity by insulin, glucocorticoid, and thyroxine in cultured fetal mouse liver. K Sato, … , T Tsushima, K Shizume J Clin Invest. 1984;74(6):2254-2262. https://doi.org/10.1172/JCI111652. Research Article To elucidate the regulatory mechanism of ontogenetic development of iodothyronine-5'-deiodinase in the fetal and neonatal period, fetal mouse liver of the 19th day of gestation, in which no iodothyronine-5'-deiodinating activity was detectable, was cultured in Dulbecco-Vogt medium supplemented with 10% thyroid hormone-depleted fetal calf serum, insulin, hydrocortisone, and thyroid hormones. Iodothyronine-5'-deiodinating activity of the homogenate was assessed by the amount of iodide released from outer-ring-labeled reverse T3 and expressed as picomoles of 127I- per milligram of protein per minute. The enzyme activity was induced in a dose-dependent manner; optimal concentrations for insulin, hydrocortisone, and thyroxine were 1 microgram/ml, 0.4 microgram/ml, and 10(-6) M, respectively. Without supplementation of either hydrocortisone or thyroxine, no 5'-deiodination was detected. The enzyme activity was observed after 3 d of culture, peaked at days 14-20, and then gradually decreased. Lineweaver-Burk analysis revealed that the increase in activity was primarily due to an increase in Vmax (day 3, 0.2 pmol/mg protein per min; day 20, 2.5 pmol/mg protein per min). Half maximal thyroxine (T4) and triiodothyronine (T3) concentrations were 1 X 10(-7) M (free T4: 4 X 10(-10) M), and 2 X 10(-9) M (free T3: 5.0 X 10(-11) M), respectively, whereas reverse T3 did not elicit any activity at 10(-8)-10(-6) M.
    [Show full text]
  • Endocrine Emergencies
    Endocrine Emergencies • Neuroendocrine response to Critical illness • Thyroid storm/Myxedema Coma • Adrenal Crisis/Sepsis • Hyper/Hypocalcemia • Hypoglycemia • Hyper and Hyponatremia • Pheochromocytoma crises CASE 76 year old man presents with urosepsis and is Admitted to MICU. He has chronic renal insufficiency. During his hospital course, he is intubated and treated With dopamine. Thyroid studies are performed for Inability to wean from ventilator. What labs do you want? Assessment of Thyroid Function • Hormone Levels: Total T4, Total T3 • Binding proteins: TBG, (T3*) Resin uptake • Free Hormone Levels: TSH, F T4, F T3, Free Thyroid Index, F T4 by Eq Dialysis • Radioactive Iodine uptake (RAIU); primarily for DDx of hyperthyroidism • Thyroid antibodies; TPO, Anti-Thyroglobulin, Thyroid stimulating immunoglobulins, Th receptor antibodies Labs: T4 2.4 ug/dl (5-12) T3U 40% (25-35) FTI 1.0 (1.2-4.2) FT4 0.6 (0.8-1.8) TSH 0.2 uU/ml (.4-5.0) Non-thyroidal illness • Hypothesis: NTI vs 2° Hypothyroidism –RT3 ↑ in NTI and ↓ in Hypothyroidism • Hypothesis: NTI vs Hyperthyroidism – TT3 ↓ in NTI and in ↑ Hyperthyroidism • 75 year old woman with history of hypothyroidism is found unresponsive in her home during a cold spell in houston. No heat in the home. • Exam: T° 95, BP 100/60, P 50, RR 8 • Periorbital edema, neck scar, no rub or gallop, distant heart sounds, crackles at bases, peripheral edema • ECG: Decreased voltage, runs of Torsade de pointes • Labs? Imaging? • CXR: cardiomegaly • Glucose 50 • Na+ 120, K+ 4, Cl 80, HCO3¯ 30 • BUN 30 Creat 1.4 • ABG: pH 7.25, PCO2 75, PO2 80 • CK 600 • Thyroid studies pending • Management: Manifestations of Myxedema Coma • Precipitated by infection, iatrogenic (surgery, sedation, diuretics) • Low thyroid studies • Hypothermia • Altered mental status • Hyponatremia • ↑pCO2 • ↑CK • ↑Catecholamines with ↑vascular resistance • Cardiac: low voltage, Pericardial effusion, impaired relaxation with ↓C.O.
    [Show full text]